Read by QxMD icon Read

PET/CT, colorectal metastases

Simon Sin-Man Wong, Wong L Yu, Ki Wang, Anil T Ahuja
AIM: To evaluate the efficacy of (18)flurodeoxyglucose positron emission tomography/computer tomography ((18)F-FDG PET/CT) in investigating patients with elevated carcinoembryonic antigen (CEA) and without known primary malignancy, and the impact of PET/CT findings on patient management. SETTING AND DESIGN: PET/CT scans done in a tertiary hospital between December 2007 and February 2012 for elevated CEA in patients without known primary malignancy were retrospectively reviewed...
July 2016: Indian Journal of Radiology & Imaging
Ur Metser, Jaydeep Halankar, Deanna Langer, Ravi Mohan, Douglas Hussey, Moshonov Hadas, Shlomit Tamir
: The largest randomized controlled trial (RCT) on the effect of FDG-PET on surgical management for metastatic colorectal adenocarcinoma to liver ("PET-CAM") reported only a modest change in surgical management (8%). PURPOSE: To explore the relationship between prior chemotherapy and detection of metastatic disease on PET in patients from PET-CAM. Secondary aim: to determine whether centralized imaging interpretation could have impacted trial results. METHODS: The study included 120 patients from a single institution...
November 15, 2016: Annals of Nuclear Medicine
Luca Viganò, Egesta Lopci, Guido Costa, Marcello Rodari, Dario Poretti, Vittorio Pedicini, Luigi Solbiati, Arturo Chiti, Guido Torzilli
BACKGROUND: The impact of fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) for patients with colorectal liver metastases (CLM) still is debated. Its relevance could be enhanced in the case of recurrent disease. The current study aimed to elucidate the role of PET-CT in restaging and treatment planning for recurrent CLM. METHODS: A series of 352 consecutive patients undergoing their first liver resection for CLM between 2005 and 2014 was reviewed...
November 2, 2016: Annals of Surgical Oncology
Rachel Falconer, Saxon Connor, Adrian Balasingam, Tim Eglinton
BACKGROUND: Positron emission tomography/computed tomography (PET/CT) is used pre-operatively in patients with metastatic or recurrent colorectal cancer to identify those who have potentially curative disease. However, a recent randomized trial questioned the added benefit of PET/CT over conventional imaging in patients with liver metastases. The aim of this study was to determine the proportion of patients with colorectal cancer in whom PET/CT altered surgical management, in a single tertiary centre...
October 27, 2016: ANZ Journal of Surgery
Andor F van den Hoven, Jip F Prince, Rutger C G Bruijnen, Helena M Verkooijen, Gerard C Krijger, Marnix G E H Lam, Maurice A A J van den Bosch
BACKGROUND: An anti-reflux catheter (ARC) may increase the tumor absorbed dose during radioembolization (RE) by elimination of particle reflux and its effects on hemodynamics. Since the catheter is fixed in a centro-luminal position, it may also increase the predictive accuracy of a scout dose administration before treatment. The purpose of the SIM trial is to compare the effects of ARC use during RE with holmium-166 ((166)Ho) microspheres in patients with colorectal liver metastases (CRLM), with the use of a standard end-hole microcatheter...
October 25, 2016: Trials
Fernanda Granato, Andre C Felicio, Lilian Yuri Itaya Yamaga, Solange Amorim Nogueira, Taise Vitor
The liver is the organ most commonly affected by colorectal cancer metastasis. Currently, liver resection is the treatment of choice, but in cases where it is not possible, intensity-modulated radiation therapy is an alternative. We report the case of a 57-year-old woman whose colorectal carcinoma metastasized to the liver. She was referred for implantation of fiducial markers for intensity-modulated radiation therapy planning. PET-CT stands out as an additional tool for distinguishing metabolically active tumor tissue from other tissues, ensuring effective introduction of percutaneous fiducial markers, especially in cases where use of conventional imaging techniques is limited...
October 21, 2016: Clinical Nuclear Medicine
Chun-Yi Wu, Jo-Hsin Tang, Pei-Chia Chan, Jia-Je Li, Ming-Hsien Lin, Chih-Chieh Shen, Ren-Shyan Liu, Hsin-Ell Wang
PURPOSE: Surgical resection is the standard treatment for localized colorectal cancer, which is the most common type of gastrointestinal cancer. However, over 40 % cases are diagnosed metastasized and apparently inoperable. Systemic chemotherapy provides an alternative to these patients. This study aims to evaluate the therapeutic potential of liposomal doxorubicin (lipoDox) in combination with liposomal vinorelbine (lipoVNB) in a CT-26 colon carcinoma-bearing mouse model. PROCEDURES: The in vitro cytotoxicity of Dox and VNB on CT-26 cancer cells was determined by MTT and colony formation assays...
October 11, 2016: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
Robert Matthews, Minsig Choi
Anatomic imaging utilizing both CT (computed tomography) and MRI (magnetic resonance imaging) limits the assessment of cancer metastases in lymph nodes and distant organs while functional imaging like PET (positron emission tomography) scan has its limitation in spatial resolution capacity. Hybrid imaging utilizing PET-CT and PET-MRI are novel imaging modalities that are changing the current landscape in cancer diagnosis, staging, and treatment response. MRI has shown to have higher sensitivity in soft tissue, head and neck pathology, and pelvic disease, as well as, detecting small metastases in the liver and bone compared to CT...
September 9, 2016: Diagnostics
Raj Mohan Paspulati, Amit Gupta
PET/computed tomography (PET/CT) is an established hybrid imaging technique for staging and follow-up of gastrointestinal (GI) tract malignancies, especially for colorectal carcinoma. Dedicated hybrid PET/MR imaging scanners are currently available for clinical use. Although they will not replace regular use of PET/CT, they may have utility in selected cases of GI tract malignancies. The superior soft tissue contrast resolution and depiction of anatomy and the functional information obtained from diffusion-weighted imaging (DWI) provided by MR imaging in PET/MR imaging are advantages over CT of PET/CT for T staging and follow-up of rectal carcinoma and for better characterization of liver lesions...
October 2016: PET Clinics
Martina Sollini, Francesco Pasqualetti, Marzio Perri, Gabriele Coraggio, Paolo Castellucci, Massimo Roncali, Roberto Boni, Elena Lazzeri, Maria Galeandro, Fabiola Paiar, Annibale Versari, Paola Anna Erba
BACKGROUND: The role of radiolabeled choline (Cho) in patients with biochemical recurrence after radical treatment for prostate cancer (PCa) is well established. Its widespread clinical use has prompted the depiction of incidentalomas, unusual sites of metastatic lesions, as well as false positive and negative cases. We reported a series of patients affected by biochemical recurrence of PCa imaged by [(18)F]Cho positron emission tomography/computed tomography (PET/CT) which resulted suspected for a second malignancy...
August 31, 2016: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
C Riola-Parada, L García-Cañamaque, V Pérez-Dueñas, M Garcerant-Tafur, J L Carreras-Delgado
OBJECTIVE: The aim of this review was to evaluate the diagnostic performance of simultaneous PET/MRI in oncology compared with that of PET/CT, based upon the available evidence. MATERIAL AND METHODS: A systematic search was performed in the Medline and Embase databases to identify original clinical articles published up to 21 January 2016, in order to compare simultaneous PET/MRI and PET/CT in oncology patients. RESULTS: A total of 57 articles were obtained that included various diseases: head and neck cancer (5), lung cancer and lung nodules (13), colorectal cancer (1), liver lesions (2), abdominal incidentalomas (1), neuroendocrine tumours (2), thyroid carcinoma (2), breast cancer (3), gynaecological cancer (2), prostate cancer (4), lymphoma (2), multiple myeloma (1), bone metastases (3), intracranial tumours (2), paediatric oncology (1) and various tumours (13)...
September 2016: Revista Española de Medicina Nuclear e Imagen Molecular
Waleed Shady, Vlasios S Sotirchos, Richard K Do, Neeta Pandit-Taskar, Jorge A Carrasquillo, Mithat Gonen, Constantinos T Sofocleous
OBJECTIVE: The purpose of the present study is to evaluate Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, tumor attenuation criteria, Choi criteria, and European Organization for Research and Treatment of Cancer (EORTC) PET criteria as measures of response and subsequent predictors of liver progression-free survival (PFS) after radioembolization (RE) of colorectal liver metastases (CLM). The study also assesses interobserver variability for measuring tumor attenuation using a single 2D ROI on a simple PACS workstation...
September 2016: AJR. American Journal of Roentgenology
Dong Ho Lee, Jeong Min Lee
Magnetic resonance imaging (MRI) is presently the modality of choice for the local staging of rectal cancer, with positron emission tomography (PET) being optional for the evaluation of colorectal cancer. Indeed, previous studies have demonstrated that liver MRI using hepatocyte-specific contrast agents can provide high diagnostic performance in the detection of colorectal cancer liver metastases. Recently, however, whole-body PET/MRI, which can provide information regarding both anatomy and metabolism, has been introduced to clinical imaging, and studies are under way to assess whether it can improve diagnostic performance for oncologic diseases as well as provide additional information regarding the disease phenotype and biology compared to conventional imaging modalities of computed tomography (CT), PET, or MRI...
June 27, 2016: Journal of Magnetic Resonance Imaging: JMRI
Pablo E Serrano, Amiram Gafni, Chu-Shu Gu, Karen Y Gulenchyn, Jim A Julian, Calvin Law, Aaron L Hendler, Carol-Anne Moulton, Steven Gallinger, Mark N Levine
PURPOSE: To evaluate whether positron emission tomography (PET) combined with computed tomography (PET-CT) is cost saving, or cost neutral, compared with conventional imaging in management of patients with resectable colorectal cancer liver metastases. METHODS: Cost evaluation of a randomized trial that compared the effect of PET-CT on surgical management of patients with resectable colorectal cancer liver metastases. Health care use data ≤ 1 year after random assignment was obtained from administrative databases...
July 2016: Journal of Oncology Practice
K Kuhlmann, J van Hilst, S Fisher, G Poston
The development of new potent systemic treatment modalities has led to a significant increase in survival of patients with colorectal liver metastases. In the neo-adjuvant setting, these modalities can be used for patient selection, down staging, and conversion from non-resectable to resectable liver metastases. In addition, complete radiological disappearance of metastases can occur, the phenomenon of disappearing liver metastases. Because only a small percentage of these patients (0-8%) have a complete radiological response of all liver metastases, most patients will undergo surgery...
May 24, 2016: European Journal of Surgical Oncology
F Edward Boas, Lynn A Brody, Joseph P Erinjeri, Hooman Yarmohammadi, Waleed Shady, Sirish Kishore, Constantinos T Sofocleous
OBJECTIVE: Colorectal liver metastases (CLM) have a variable response to radioembolization. This may be due at least partly to differences in tumor arterial perfusion. The present study examines whether quantitative measurements of enhancement on preprocedure triphasic CT can be used to predict the response of CLM to radioembolization. MATERIALS AND METHODS: We retrospectively reviewed patients with CLM treated with radioembolization who underwent pretreatment PET/CT and triphasic CT examinations and posttreatment PET/CT examinations...
September 2016: AJR. American Journal of Roentgenology
Karin Nielsen, Hester J Scheffer, José H Volders, Maurice J D L van der Vorst, Aukje A J M van Tilborg, Emile Fi Comans, E S M de Lange-de Klerk, Colin Sietses, Sybren Meijer, Martijn R Meijerink, M Petrousjka van den Tol
INTRODUCTION: Systemic chemotherapy is able to convert colorectal liver metastases (CRLM) that are initially unsuitable for local treatment into locally treatable disease. Surgical resection further improves survival in these patients. Our aim was to evaluate disease-free survival (DFS), overall survival, and morbidity for patients with CRLM treated with RFA following effective downstaging by chemotherapy, and to identify factors associated with recurrence and survival. MATERIALS AND METHODS: Included patients had liver-dominant CRLM initially unsuitable for local treatment but eligible for RFA or RFA with resection after downstaging by systemic chemotherapy...
August 2016: World Journal of Surgery
Stephanie Downs-Canner, Zong Sheng Guo, Roshni Ravindranathan, Caroline J Breitbach, Mark E O'Malley, Heather L Jones, Anne Moon, Judith Andrea McCart, Yongli Shuai, Herbert J Zeh, David L Bartlett
We have conducted a phase 1 study of intravenous vvDD, a Western Reserve strain oncolytic vaccinia virus, on 11 patients with standard treatment-refractory advanced colorectal or other solid cancers. The primary endpoints were maximum tolerated dose and associated toxicity while secondary endpoints were pharmacokinetics, pharmacodynamics, immune responses, and antitumor activity. No dose-limiting toxicities and treatment related severe adverse events were observed. The most common adverse events were grades 1/2 flu-like symptoms...
August 2016: Molecular Therapy: the Journal of the American Society of Gene Therapy
Vankadari Kousik, Pankaj Promila, Ritu Verma, Arun Gupta
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is the sixth most common cancer and third leading cause of cancer-related death in the world. The management of unresectable HCC and hepatic metastases from various solid tumors is a clinical dilemma. There is paucity of data on the treatment of unresectable HCC and hepatic metastases with yttrium-90 (90Y) radioembolization. METHODS: Thirty patients (mean age; 55.2 years; range 43-82 years) comprising 21 patients with HCC (12 patients have cirrhosis of which 3 patients belong to Child-Pugh class A and 9 patients belong to Child-Pugh class B), 7 patients with metastasis from colorectal cancer, 1 patient with metastasis from melanoma, and 1 patient with metastasis from ovarian carcinoma underwent resin-based 90Y radioembolization between 2013 and 2015 in our study...
May 2016: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
Waleed Shady, Sirish Kishore, Somali Gavane, Richard K Do, Joseph R Osborne, Gary A Ulaner, Mithat Gonen, Etay Ziv, Franz E Boas, Constantinos T Sofocleous
PURPOSE: To compare the performance of 4 metrics of metabolic response on FDG-PET/CT against RECIST 1.0 for determining response and predicting overall survival (OS) following (90)Y resin microspheres radioembolization of colorectal liver metastases (CLM). METHODS: We conducted an IRB-waived retrospective review of our radioembolization database to identify patients with unresectable CLM treated between December 2009 and December 2013. We included patients who had both PET/CT and contrast enhanced CT (CECT) available at baseline and on the first follow-up post-radioembolization...
June 2016: European Journal of Radiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"